BioCryst (BCRX) surges on flu drug trial results
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX), the life-sciences component of Stockhouse wealth service Ticker Trax (TM), soared 41% to $5.95 Friday, after the Birmingham, Alabama-based biotech firm announced positive results from two Phase 3 studies of its influenza treatment, intravenous peramivir, in patients with seasonal flu.
Biotech firm gains on H1N1 vaccine study results
Quebec-based biotechnology company Medicago (TSX: V.MDG) announced results Tuesday from an immunogenicity study in mice with its new vaccine candidate for the influenza A (H1N1) virus.
BioCryst Pharmaceuticals down Wednesday after 140% surge
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) gave back some of this week’s impressive gains Wednesday, down 18.6% to $3.40, while news of the swine flu continued to dominate headlines.
Swine Flu Reports Pose Dangers to Portfolios
Markets in this early stage of a possible pandemic already have indicated winners.
Noveko, Medicago surge
Shares of air filter, face mask and antimicrobial product developer Noveko International (TSX: T.EKO) surged 41% Monday morning to $2.68.
